Patents Assigned to Cartesian Therapeutics, Inc.
-
Publication number: 20250177360Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.Type: ApplicationFiled: June 28, 2024Publication date: June 5, 2025Applicant: Cartesian Therapeutics, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20250152561Abstract: Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin/hydrophobic polyester carrier material in the composition.Type: ApplicationFiled: October 21, 2024Publication date: May 15, 2025Applicant: Cartesian Therapeutics, Inc.Inventors: Conlin O'Neil, Aaron P. Griset, David H. Altreuter
-
Publication number: 20250108094Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.Type: ApplicationFiled: September 9, 2024Publication date: April 3, 2025Applicant: Cartesian Therapeutics, Inc.Inventor: Lloyd Johnston
-
Publication number: 20250090451Abstract: Provided herein are methods and compositions and kits related to uricase compositions and/or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.Type: ApplicationFiled: August 29, 2024Publication date: March 20, 2025Applicant: Cartesian Therapeutics, Inc.Inventors: Lloyd Johnston, Takashi Kei Kishimoto, Werner Cautreels, Earl Sands
-
Publication number: 20250057756Abstract: Provided herein are methods and compositions and kits related to uricase compositions and/or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.Type: ApplicationFiled: October 31, 2024Publication date: February 20, 2025Applicant: Cartesian Therapeutics, Inc.Inventors: Lloyd Johnston, Takashi Kei Kishimoto, Werner Cautreels, Earl Sands
-
Patent number: 12194078Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.Type: GrantFiled: July 21, 2022Date of Patent: January 14, 2025Assignee: Cartesian Therapeutics, Inc.Inventor: Lloyd Johnston
-
Publication number: 20240344030Abstract: Provided here are cells engineered for therapeutic purposes to express multiple proteins, including an anti-BCMA (B cell maturation antigen), anti-CD3 bispecific antibody. Also provided are new anti-BCMA, anti-CD3 bispecific antibodies with associated sequences. Further disclosed is a mesenchymal stem cell (MSC) comprising an exogenous mRNA encoding an anti-BCMA and anti-CD3 antibody, and an exogenous mRNA encoding a single-chain interleukin-12 (IL-12) fusion protein.Type: ApplicationFiled: July 28, 2022Publication date: October 17, 2024Applicant: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Sjaji Daniel, Murat V. Kalayoglu, Minhtran Ngo Casi
-
Publication number: 20240294600Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.Type: ApplicationFiled: May 3, 2024Publication date: September 5, 2024Applicant: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
-
Patent number: 11999773Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.Type: GrantFiled: December 2, 2021Date of Patent: June 4, 2024Assignee: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
-
Publication number: 20230174944Abstract: Provided herein are mammalian cells comprising a first exogenous nucleic acid encoding a DNAse protein and a second exogenous nucleic acid encoding another DNAse protein, such as DNASE1 protein and DNASE1L3 protein, that have improved properties, including the ability to degrades extracellular chromatin and remove Neutrophil Extracellular Traps (NETs). Use of these cells, including the use in the treatment of a subject in need thereof, is also contemplated.Type: ApplicationFiled: April 15, 2021Publication date: June 8, 2023Applicant: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Shaji Daniel, Metin Kurtoglu, Murat V. Kalayoglu
-
Publication number: 20220089678Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.Type: ApplicationFiled: December 2, 2021Publication date: March 24, 2022Applicant: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
-
Patent number: 11220535Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.Type: GrantFiled: January 22, 2021Date of Patent: January 11, 2022Assignee: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
-
Publication number: 20210221868Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.Type: ApplicationFiled: January 22, 2021Publication date: July 22, 2021Applicant: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat Kalayoglu, Michael S. Singer
-
Patent number: 10934337Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.Type: GrantFiled: March 20, 2020Date of Patent: March 2, 2021Assignee: Cartesian Therapeutics, Inc.Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
-
Publication number: 20190030073Abstract: The invention provides a cellular immunotherapy therapy product comprising CAR T cells that are enriched in CD8+ cells. Also provided are methods for making and using the product.Type: ApplicationFiled: December 1, 2017Publication date: January 31, 2019Applicant: Cartesian Therapeutics, Inc.Inventors: Murat V. Kalayoglu, Metin Kurtoglu
